Synlogic Company Description

Synlogic, Inc., a biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States.

Its pipeline include SYNB1618 for the treatment of phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout.

The company has a collaboration agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Ginkgo Bioworks, Inc. Synlogic, Inc. is based in Winchester, Massachusetts.

Synlogic, Inc.

Country	United States
Industry	Biological Products, Except Diagnostic Substances
Employees	1
CEO	Mary Dooley

Contact Details

Address: PO Box 30 Winchester, Delaware 01890 United States
Phone	617 659 2802
Website	synlogictx.com

Stock Details

Ticker Symbol	0A8U
Exchange	London Stock Exchange
Fiscal Year	January - December
Reporting Currency	USD
SIC Code	2836

Key Executives

Name	Position
Mary Dooley	Chief Executive Officer
Mary Dooley	Chief Financial Officer